Senti Biosciences Holdings (SNTI) Enterprise Value (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Enterprise Value of -$16.4 million for Q4 2025, up 66.05% year-over-year from -$9.9 million in Q4 2024, and down 33.95% quarter-over-quarter from -$12.2 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Enterprise Value (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Enterprise Value history runs 5 years deep, the most recent figure standing at -$16.4 million for Q4 2025.
- In Q4 2025, Enterprise Value rose 66.05% year-over-year to -$16.4 million; the TTM figure through Dec 2025 stood at -$16.4 million (up 66.05% YoY), while the FY2025 annual figure was -$16.4 million, up 66.05% from the prior year.
- Enterprise Value for Q4 2025 stood at -$16.4 million, down from -$12.2 million in the prior quarter.
- The five-year high for Enterprise Value was -$10.5 million in Q3 2024, with the low at -$139.8 million in Q2 2022.
- The 5-year median for Enterprise Value is -$39.4 million (2023), against an average of -$52.5 million.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value sank 99.54% in 2023, then surged 73.37% in 2024.
- Senti Biosciences Holdings' Enterprise Value stood at -$56.0 million in 2021, then tumbled by 75.9% to -$98.6 million in 2022, then surged by 63.55% to -$35.9 million in 2023, then plunged by 34.44% to -$48.3 million in 2024, then soared by 66.05% to -$16.4 million in 2025.
- Business Quant data shows SNTI's Enterprise Value at -$16.4 million in Q4 2025, -$12.2 million in Q3 2025, and -$21.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 2.12 Bn |
| 10 | Senti Biosciences Holdings | 12.61 Mn | 12.61 Mn | - | -6.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16.40 Mn |
| Sep 30, 2025 | -12.24 Mn |
| Jun 30, 2025 | -21.60 Mn |
| Mar 31, 2025 | -33.80 Mn |
| Dec 31, 2024 | -48.30 Mn |
| Sep 30, 2024 | -10.50 Mn |
| Jun 30, 2024 | -15.90 Mn |
| Mar 31, 2024 | -23.70 Mn |
| Dec 31, 2023 | -35.93 Mn |
| Sep 30, 2023 | -39.43 Mn |
| Jun 30, 2023 | -59.64 Mn |
| Mar 31, 2023 | -76.11 Mn |
| Dec 31, 2022 | -98.56 Mn |
| Sep 30, 2022 | -114.94 Mn |
| Jun 30, 2022 | -139.80 Mn |
| Mar 31, 2022 | -38.14 Mn |
| Dec 31, 2021 | -56.03 Mn |
| Sep 30, 2021 | -73.69 Mn |
| Jun 30, 2021 | -82.94 Mn |